A recent study investigates the ability of an asthma drug to reduce levels of α-synuclein, a protein believed to contribute to the development of Parkinson’s disease.
US regulators have approved the first and only treatment option to treat dyskinaesia in patients with Parkinson's disease.
Titan Pharmaceuticals’ stated today that their ropinirole implant, designed to treat the symptoms of Parkinson’s disease, was cleared by the FDA today as a new drug application.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.